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aa, 315 kDa, type-1 transmembrane receptor expressed on
the cell surface and in intracellular (e.g. endocytic) compartments. The receptor is composed of modular repeats of epidermal growth factor (EGF), EGF-like and Fasciclin domains.
Native tissues express two HARE isoforms of different mass
(190 kDa and 315 kDa) that are not splice variants (Zhou et
al. 1999, 2003; Weigel et al. 2002). In cells stably expressing
cDNA encoding full-length 315-HARE, a small fraction of the
315 kDa protein is proteolytically cleaved to create the 190HARE, the C-terminal 1416 aa of the 315-HARE protein (Harris et al. 2007). Both HARE isoforms are functional endocytic
receptors, targeted to coated pits, with identical ligand-binding profiles (Harris et al. 2004, 2007; Harris and Weigel 2008).
A defining feature of HARE is its Link domain, 168 aa from
the membrane domain, which has a sequence similar to Link
domains in other HA-binding proteins such as TSG-6, CD44
and aggrecan (Day and Prestwich 2002).
HARE recognizes at least 13 distinct ligands, including
HA (Yannariello-Brown et al. 1997; Politz et al. 2002), collagen N-terminal propeptides (Hansen et al. 2005), advanced
glycation end-products (Tamura et al. 2003), acetylated low
density lipoprotein (Adachi and Tsujimoto 2002), chondroitin and chondroitin sulfates type A–E (Harris et al. 2004),
αMβ2 integrin (Jung et al. 2007), heparin (Harris et al. 2008)
and phosphatidylserine (Park et al. 2008a). The function of
HARE/Stab2 in liver and lymph nodes to remove circulating
HA and chondroitin sulfates has been known for over two
decades. However, three recent findings indicate that HARE
mediates additional important functions: i) HARE mediates
intracellular ERK signaling in response to HA binding (Kyosseva et al. 2008); ii) HARE is the long-sought macrophage
apoptotic receptor that recognizes exposed phosphatidylserine on dying cells and mediates their phagocytosis (Park et
al. 2008a, 2008b); and iii) HARE is the major liver clearance
receptor for circulating heparin (Harris et al. 2008, 2009).

Abstract
The hyaluronic acid receptor for endocytosis (HARE)/Stabilin-2 is the primary systemic scavenger receptor for 13 ligands including hyaluronan (HA), heparin and chondroitin sulfates. Most ligand-binding sites are within the 190 kDa
isoform, which contains ~25 kDa of N-glycans and is the Cterminal half of the full-length 315 kDa HARE. Glycoproteomic analyses of purified recombinant human 190-HARE
ecto-domain identified a diverse population of glycans at 10
of 17 consensus sites. The most diversity (and the only sialylated structures) occurred at N2280, within the HA-binding
Link domain. To determine if these N-glycans are required
for HA binding, we created human Flp-In 293 cell lines expressing membrane-bound or soluble ecto-domain variants of
190-HARE(N2280A). Membrane-bound HARE lacking Link
domain N-glycans mediated rapid HA endocytosis, but purified 190-HARE(N2280A) ecto-domain showed little or no HA
binding in ELISA-like, HA-HARE pull-down assays or by surface plasmon resonance analysis (which detected very high
apparent affinity for 190-HARE ecto-domain binding to HA;
Kd = 5.2 nM). The results indicate that Link domain N-glycans
stabilize interactions that facilitate HA binding to HARE.
Keywords: coated pit mediated, conformation, glycosaminoglycan turnover, HA binding affinity, Stabilin-2

Introduction
The hyaluronic acid (HA) receptor for endocytosis (HARE),
also known as Stabilin-2 or FEEL-2, is a clearance/scavenger
receptor that is highly expressed in the sinusoidal endothelial
cells of liver, lymph node and spleen (Weigel and Yik 2002).
HARE is also found in oviduct, corneal and lens epithelium,
heart valve mesenchymal cells, ependymal cells lining ventricles in brain, macrophages and epithelial cells covering renal papillae (Falkowski et al. 2003). Human HARE is a 2551
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Figure 1. Glycomic analysis of s190-HARE. MALDI-TOF mass spectrum of permethylated s190-HARE N-glycans. N-Glycans were derived from
the 50% (v/v) acetonitrile fraction from a C18 Sep-Pak. All molecular ions are [M+-Na]+-, and nominal masses of the 12C isotope are shown. The
putative structures shown are based on composition, tandem mass spectrometry analysis and knowledge of biosynthetic pathways. Symbol code:
Gal (yellow circle), Man (green circle), GlcNAc (blue square), Fuc (red triangle) and NeuAc (purple diamond)

The large size of HARE and its recognition of multiple ligands present challenges in efforts to define subdomains
within the protein that mediate specific ligand-binding
events. Considerable additional complexity is contributed by
earlier findings that the 190-HARE and 315-HARE glycoproteins contain >25 kDa in N-glycans (Weigel and Weigel 2003;
Zhou et al. 2003). Within the 190-HARE, 13 consensus N-glycosylation sites are conserved among rat, mouse and human
(including one NCTC site). In order to express and characterize stable HARE subdomains that retain a specific ligandbinding activity, it is important to know more about HARE
N-glycans, the sites that are modified and if N-glycans at
particular sites are important for ligand binding.
Our goals in this study were to identify the types of Nglycans at occupied Asn sites in 190-HARE and to determine if glycans at N2280 in the Link domain are required for
HA binding by purified ecto-domain or membrane-bound
receptor.
Results
Glycomics analysis of s190-HARE
Recombinant soluble 190-HARE ecto-domain protein (s190HARE), containing C-terminal His-6 and V5 tags, was expressed in human Flp-In 293 cells, purified from media and

analyzed by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE). The s190-HARE band was excised, digested with trypsin and then with PNGase-F. The
released N-glycans were separated from peptides by SepPak C18 purification, permethylated and analyzed by matrix-assisted laser desorption ionization time-of-flight mass
spectrometry (MALDI-TOF MS) (Figure 1). For each ion, putative structural assignments were made based on compositional information and knowledge of mammalian glycosylation biosynthetic pathways. Where possible, components
observed in the MALDI-MS profile (Figure 1) were subjected
to electrospray ionization tandem mass spectrometry (ESIMS/MS) to assist sequence assignment (not shown).
The mass spectrum indicates that s190-HARE N-glycans
have compositions consistent with minor amounts of high
mannose structures (Hex5–7HexNAc2) plus major complex
type bi-, tri- and tetra-antennary glycans of compositions
NeuAc0–2Fuc0–2Hex3–7HexNAc4–7. The most abundant ion
(m/z 2285) has a composition (Fuc1Hex4HexNAc5) consistent with either a core fucosylated bisected bi-antennary glycan or a core fucosylated tri-antennary glycan, each having
a single antenna terminated with galactose (Figure 1). The
next two most abundant components (m/z 2244 and 2489;
Figure 1), 70% and 50% of the base (highest) peak, respectively, have two antennae capped with galactose. Many com-
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Figure 2. N-Glycosylation sites and N-glycans identified in s190-HARE. The glycans observed at the indicated sites are shown; numbering is based
on the full-length 2551 aa HARE. The glycan structures are based on the composition of the glycan, as calculated from the mass of the glycopeptide minus the mass of the peptide, complemented by information from CAD-ESI-MS/MS data and from the glycomic profile shown in Figure 1.
Symbol code: Gal (yellow circle), Man (green circle), GlcNAc (blue square), Fuc (red triangle) and NeuAc (purple diamond)

ponents are of more modest abundance. Those showing signals greater than 5% of the base peak include glycans lacking
fucose (for example m/z 2070 and 2111; Figure 1), and constituents whose compositions are consistent with the presence of a fucosylated antenna in addition to core fucose (m/z
2418 and 2459; Figure 1). Very few glycans are sialylated,
and based on comparisons of peak heights, they constitute
less than 5% of the total population. Most sialylated glycans
have only a single sialic acid (m/z 2605, 3055 and 3504; Figure 1), although a trace amount of a disialyl component was
identified at m/z 3865.
Glycoproteomic analysis of s190-HARE
We performed extensive glycoproteomic analyses on gel-purified s190-HARE protein using a variety of proteases, alone
and in combinations, as well as chemical cleavage. Resulting peptides were analyzed by nano-liquid chromatography
(LC)-ESI-MS/MS. As glycosidic bond fragmentation occurs
during collisional activation in ESI-MS/MS and results in diagnostic fragment ions at m/z 204 (HexNAc) and 366 (HexHexNAc), MS/MS spectra were analyzed for these ions, and
when present the spectra were examined manually to identify the glycopeptide. Using this technique, we identified

the populations of N-glycans at 10 of the 17 consensus sites
for N-glycosylation (Figure 2). Of the 10 sites, two are localized to regions of special biological interest. The first important site is at N2280KS within the HA-binding Link region.
Although the HARE Link domain has not been independently expressed and assessed directly for HA-binding activity, cells expressing a 190-HARE(ΔLink) mutant endocytose
<10% of the HA endocytosed by wild type (WT) 190-HARE
cells (Kyosseva et al. 2008; Harris and Weigel 2008). The
N2280 site is occupied by a very heterogeneous range of Nglycans with and without sialic acid. In fact, all the sialylated
structures identified were found only at N2280. N-Glycans
with compositions consistent with bisected structures are
also a feature of the glycan population at N2280 (Figure 2). A
second site of presumed importance is N2296, which is in the
stem region between the Link and membrane domains. This
site carries the most homogeneous range of N-glycans of all
the identified sites, having a limited number of small neutral glycans with compositions Fuc0–1Hex4–5HexNAc4–5 (Figure 2). The N2296CT site is also unusual in that it overlaps a
CTC sequence, both of which are conserved. In such cases,
disulfide bond formation might preclude glycosylation and
vice versa.
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Figure 3. Estimation of s190-HARE N-glycan content. A. Glycosylation
of HARE during biosynthesis. Cells expressing either membranebound 190-HARE (top) or 315-HARE (bottom) were incubated with
35S-Met/Cys for 5 min, washed and then incubated (chased) for the indicated times with fresh DMEM as described in Materials and methods. HARE proteins were purified using mAb-30, separated by SDS–
PAGE, and the gels were processed for autoradiography. The nascent
HARE core proteins (solid arrows) are shifted to larger mass (open arrows) as they are glycosylated and move from the ER/Golgi to the cell
surface. B. Effect of reduction on N-glycan release from s190-HARE.
Purified s190-HARE was untreated (lanes 1 and 2) or reduced and
alkylated (lanes 3 and 4) and then incubated with (lanes 2 and 4) or
without (lanes 1 and 3) PNGase-F. Samples were separated by SDS–
PAGE, electro-blotted to nitrocellulose, and HARE was detected using
anti-V5 Ab. C. Effect of chemical or enzymatic deglycoslyation. Purified s190-HARE was reduced and alkylated and then either untreated
(lane 2) or treated with TMFS (lane 1), PNGase-F (lane 3) or Endo-H
(lane 4) and analyzed as above.

In addition to N-glycopeptides observed during the
LC-ESI-MS/MS analysis of s190-HARE, ions consistent
with two O-glycopeptide glycoforms were also detected.
The data were attributable to the peptide CLPAYTGDGKVCTL1555 carrying O-glycans with compositions HexNAc
and HexHexNAc. Peptide fragmentation enabled sequencing through most of the peptide and assignment of T1547 as
the substituted residue (not shown). We do not know what
other sites may also be O-glycosylated, but results shown below confirm that s190-HARE contains only a few O-glycans.
Estimation of HARE N-glycan content
Based on treatment of nonreduced protein with PNGase-F, we
concluded that the two isoforms of purified native rat and human HARE contain ~25 kDa of N-glycans (Zhou et al. 2000,
2003; Weigel and Weigel 2003), equivalent to ~10 oligosaccharides. To complement the present glycomics analysis, we determined if similar results were obtained for recombinant WT
190-HARE and 315-HARE during biosynthesis. Metabolic
pulse-chase labeling of human Flp-In 293 cells expressing 190-
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Figure 4. 190-HARE(N2280A) cells coexpress a smaller variant with
altered glycosylation that is delivered to the surface. A. Although
HARE expression levels varied among the indicated stable cell lines,
each expressed two membrane-bound 190-HARE(N2280A) bands
that bind 125I-HA in ligand blot (LB) assays. After exposure on film,
western blot (WB) analysis with anti-V5 Ab visualized the HARE
doublet. B. Both 190-HARE(N2280A) variants are on the cell surface. 190-HARE(N2280A) cells were incubated for 1 h at 4°C with
HBSS containing 1 μg/mL mAb-30 with 0.055% digitonin (Weigel et
al. 1983) [permeabilized to assess Total] or without [nonpermeabilized to assess Surface only]. Solubilized Ab-HARE complexes were
captured using Protein A/G Sepharose. After centrifugation, the
resin was eluted with 2× Laemmli buffer (Laemmli 1970), and the eluate was separated by SDS–PAGE, electro-blotted and HARE proteins detected by enhanced chemiluminescence using anti-V5 Ab. The
ratios of the two HARE bands recovered in each lane were the same
as assessed in digital images, and the Total signal was attenuated by
~80% for comparison to the Surface signal (Harris et al. 2004, 2007).
C. The smaller band has immature glycans. Immuno-purified nonreduced s190-HARE(N2280A) protein was subjected to SDS–PAGE after
no treatment (lane 1) or digestion with PNGase-F (lane 2) or Endo-H
(lane 3). The arrow indicates the minor smaller band, which was completely shifted by Endo-H, which did not affect the larger band.

HARE or 315-HARE with 35S-Met/Cys revealed increased
sizes of 190-HARE and 315-HARE between 60 and 120 min
(Figure 3A), as expected for the addition and assembly of Nglycans in the ER/Golgi. After 2 h, most labeled protein was
~25 kDa larger than the initial core protein.
PNGase-F treatment of purified and reduced s190HARE also released ~25 kDa of N-glycans (Figure 3B), indicating that the majority of N-glycans are in the C-terminal 190-HARE portion of 315-HARE. We also determined if
some N-glycans were not released from the folded protein
by comparing protein mass shifts after digestion of reduced
or nonreduced HARE. Reduced and alkylated s190-HARE
shifted from ~150 kDa (Figure 3B, lane 1) to ~170 kDa (Figure 3B, lane 3), and the mass loss of ~25 kDa after PNGaseF treatment was similar for reduced and nonreduced receptor (Figure 3B, lanes 2 and 4). The mass of Endo-H-treated
s190-HARE was identical to that of undigested protein (Figure 3C, lanes 2 and 4), indicating that essentially all WT s190HARE N-linked glycans are mature complex structures with
few high mannose or immature N-glycans (consistent with
the glycomics analysis; Figure 1). To assess the amount of
O-glycans or PNGase-F-resistant N-glycans present, we
also treated the protein with trifluoromethanesulfonic acid
(TFMS) to release all glycans (Edge et al. 1981). TFMS-treated
and PNGase-F-treated s190-HARE proteins differed by only
4 kDa (Figure 3C, lanes 1 and 3), indicating that s190-HARE
has little O-glycosylation.
Cell lines expressing 190-HARE(N2280A)
To determine if Link domain N-glycans are required for
function, we made cDNA variants of ecto-domain or membrane-bound 190-HARE with a single N(2280)A mutation to
eliminate N-glycosylation at N2280KS. We characterized multiple stably transfected Flp-In 293 cell lines expressing ei-
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ther 190-HARE variant. In all clones examined (Figure 4A,
top), membrane 190-HARE(N2280A) was a doublet (separated by ~10 kDa), unlike WT 190-HARE (Figure 4A, last
lane); the major upper band migrated at the WT position.
Both HARE bands bound 125I-HA in a ligand blot assay (Figure 4A, bottom).
Since the smaller 190-HARE(N2280A) binds HA, it might
also mediate HA endocytosis. Although this could not be
tested directly (due to endocytosis mediated by the normal
variant), we determined if the smaller variant is delivered
to the cell surface. Cultured cells were incubated at 4°C with
HARE-specific mAb-30 (Zhou et al. 2000), with or without
digitonin, to monitor HARE recovery from intact or permeabilized cells (Weigel et al. 1983), respectively. HARE-antibody
(Ab) complexes were then solubilized, captured using Protein A/G Sepharose and analyzed by SDS–PAGE and western blotting (Figure 4B). Since the intracellular receptor pool
is 5–6-fold greater than the surface pool (Harris et al. 2004,
2007), the Total HARE signals (Figure 4B) were adjusted by
this factor to compare the two doublet bands. The fraction of
the smaller HARE band recovered by mAb bound to cell surfaces only (no digitionin) was identical to that for mAb bound
to intracellular and surface HARE (digitonin-permeabilized).
Thus, the smaller 190-HARE(N2280A) species is not a biosynthetic intermediate; it is a folded glycoform (different than
WT) that traffics normally to the cell surface.
To test if the lack of N-glycans at N2280 alters the normal
processing of 190-HARE(N2280A) proteins during biosynthesis (e.g. proteolysis or smaller N-glycans), we assessed the size
of the two s190-HARE(N2280A) proteins after treating purified receptor with PNGase-F or Endo-H to release, respectively, almost all or only immature (e.g. high mannose) glycans. Digestion with PNGase-F collapsed the doublet into
a single band (Figure 4C, lanes 1 and 2), demonstrating that
proteolysis had not occurred. Endo-H digestion quantitatively
shifted the mass of the smaller HARE band but, as expected,
not the larger normal band (Figure 4C, lanes 1, 2 and 3). The
broad PNGase-F treated band (lane 2) still contains N-glycans,
whereas the Endo-H product (lane 3) does not, since PNGaseF digestion of reduced and alkylated doublet yielded one protein of the same size as the small band in lane 3 (not shown).
Cells expressing 190-HARE(N2280A) mediate HA
endocytosis
Previous studies showed that Flp-In 293 cells expressing either HARE isoform show robust binding and coated pitmediated endocytosis of HA, whereas mock or empty vector (EV) transfected cells show essentially no specific HA
binding or endocystosis, and HA uptake is reduced >90% in
190-HARE(ΔLink) cells compared to WT (Harris et al. 2004,
2007; Harris and Weigel 2008; Kyosseva et al. 2008; Pandey
et al. 2008). Cells expressing 190-HARE lacking N2280-glycans also mediated specific binding and endocytosis of 125IHA (Figure 5). Five cell lines expressing the N2280 variant
each internalized HA rapidly and efficiently, with linear kinetics similar to WT and at similar rates (±30%), for at least
7 h (data were normalized for total HARE content relative
to WT at 100%; Figure 5). During this time, the cell surface
190-HARE pool would be internalized and recycled back to
the surface ~46 times (Harris et al. 2004). In contrast, the specific HA uptake rate by EV and 190-HARE(ΔLink) cells was
−1.2% and 2.8%, respectively, of WT. The variability in HA
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Figure 5. Cell lines expressing 190-HARE(N2280A) endocytose
HA normally. WT 190-HARE, EV, 190-HARE(ΔLink) cells and five
190-HARE(N2280A) cell lines, indicated by different numbers, were
incubated for up to 7 h at 37°C with 125I-HA (plus or minus excess unlabeled HA) and processed at the indicated times to assess specific HA
endocytosis as described in Materials and methods. Specific endocytosis values are presented as mean (n = 3) CPM/μg cell lysate protein,
normalized for HARE expression relative to WT, which was 100%.
SEM values for nearly all data points were within ± 4% and all SEM
values were within < ± 6.3%.

uptake rates by variant HARE cell lines may reflect unique
clonal differences in the function of the complex cellular
pathways for coated pit-mediated endocytosis and receptor recycling (Harris et al. 2004). The results indicate that the
ability of membrane-bound HARE(N2280A) variant to bind
and mediate endocytosis of HA is not affected by lack of the
Link domain N-glycans.
Purified soluble 190-HARE(N2280A) ecto-domain does not
bind HA in three in vitro assays
All s190-HARE(N2280A) cell lines tested expressed the ectodomain as a single band that bound HA in a ligand blot assay
(Figure 6A), and no differences were seen in overall glycosylation due to loss of a glycan at N2280 (not shown); the glycan mass at N2280 is <4 kDa. Membrane 190-HARE(N2280A)
and WT 190-HARE bind HA similarly in ligand blot assays
and internalize HA in a similar fashion (Figures 4A and 5).
There were also no differences in HA-binding ability of the
soluble and membrane 190-HARE(N2280A) proteins in ligand blot assays (Figure 6A).
In contrast, three other independent methods to evaluate
HA-binding activity showed that the s190-HARE(N2280A)
ecto-domain binds much less or no HA compared to WT
ecto-domain (Figure 6B–D). The negative control was s190HARE(Δlink), which does not bind HA. In a HARE pulldown assay, using biotin (b)-HA bound to SA-Agarose,
two independent purified s190-HARE(N2280A) preparations showed only a trace of HA binding, whereas all
the WT s190-HARE present, but no s190-HARE(Δlink),
bound to HA (Figure 6B). Similarly, in an ELISA-like assay,
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s190-HARE(N2280A) binding to immobilized HA was only
18% of the WT value (Figure 6C). Finally, we used surface plasmon resonance (SPR) with b-HA as the ligand, attached to a SA chip, to quantify HA binding to each of the
three ecto-domains used as the analyte (Figure 6D). No detectable binding to HA was observed for either the s190HARE(N2280A) or the s190-HARE(ΔLink) ecto-domains
(Figure 6D, middle and bottom panels). In contrast, WT
s190-HARE bound HA in a reversible manner (Figure 6D,
top panel) with exceptionally high apparent affinity (Kd =
5.2 nM) calculated from the measured kinetic values for
kon (1.58 × 105 s−1 mol−1) and koff (8.22 × 10−4 s−1). This affinity of HARE binding to HA is the highest of all known
hyalectins.
Discussion

Figure 6. The 190-HARE(N2280A) ecto-domain does not bind HA in
most assays. A. Ligand blot assay. Soluble (SOL) s190-HARE(N2280A)
is a single band by western blot (WB) that is smaller than membranebound (MEM) 190-HARE(N2280A). Both bind 125I-HA in ligand
blot (LB) assays. B. HARE pull-down assay. SA-agarose with bound
b-HA was incubated with 1 μg of purified s190-HARE [WT], s190HARE(ΔLink) [ΔL] or s190-HARE(N2280A) [N-A; two different preparations] C. ELISA-like assay. Binding of the three purified ecto-domains to HA immobilized on plate wells was quantified by A405 as
described in “Materials and methods.” D. Surface plasmon resonance
assay. The three purified ecto-domains at 12.5 nM (lower lines) and
50 nM (upper lines) were each analyzed for binding to immobilized
HA and then, after 60–90 s, for dissociation in buffer without ecto-domain as described in “Materials and methods.”

We wanted to determine if the HARE Link domain is N-glycosylated and, if so, whether these N-glycans are required
for HA binding. Two of the present findings indicate an unexpected complexity and importance for the physiological functions of HARE Link module N-glycans. First, of 10
glycosylated sites within the 190-HARE identified to contain multiple N-glycoforms, N2280 in the Link domain site
showed the greatest structural diversity and was the only
site with sialylated glycans. Second, although membranebound 190-HARE(N2280A) binds and endocytoses HA normally, the ecto-domain shows impaired or no HA binding in
three of four in vitro assays.
HARE has the highest apparent affinity for binding to HA
(Kd = 5–23 nM; Figure 6D and Harris et al. 2004, 2007) of all
hyalectins, surpassing CD44 [Kd = 5–150 µM (Skelton et al.
1998)], TSG-6 [Kd = 200–500 nM (Kahmann et al. 2000)], aggrecan [Kd = 226 nM (Watanabe et al. 1997)] and Link protein [Kd = 82 nM (Watanabe et al. 1997)]. These values are
all apparent (van der Merwe et al. 1993) since the presence
of dimers and oligomers in the purified proteins is generally unknown and the HA ligand is inherently multivalent.
Nonetheless, the Kd value of 5 nM determined here from SPR
data (Figure 6D) is in excellent agreement with previously
determined Kd values of 10 nM and 22 nM for HA binding to
purified s315-HARE and s190-HARE, respectively, in ELISAlike assays (Harris et al. 2007), and of 7 nM for HA binding
to membrane-bound 190-HARE in cells (Harris et al. 2004).
Both HARE isoforms have identical affinities for binding
to heparin or HA and identical binding profiles for at least
six other ligands (Harris and Weigel 2008). More than 90% of
the HA-binding activity of HARE is lost in the HARE(ΔLink)
variant (Kyosseva et al. 2008). CS-A, CS-C and CS-D also
bind within the HA-binding Link domain of HARE (Harris
et al. 2004, 2007; Harris and Weigel 2008). In contrast, s190HARE(ΔLink) still binds to acetylated low density lipoprotein, heparin, dermatan sulfate (CS-B) and CS-E. Thus, HARE
specifically binds to HA and heparin at two independent and
nonoverlapping sites. Not all Link modules that bind both HA
and heparin show independent binding. For example, unlike
HARE (Harris and Weigel 2008; Harris et al. 2008), the TSG-6
Link module binds each ligand in separate grooves, but HA
binding prevents heparin binding or vice versa; HA and heparin do not bind simultaneously (Mahoney et al. 2005).
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Human 315-HARE has 28 predicted N-glycosylation sites,
of which 17 are within the 190-HARE. Our glycoproteomic
results identified multiple types of glycans on 10 of these 17
sites. Of these 10 human glycosylation sites, nine are conserved in rat and mouse HARE (Zhou et al. 2002, 2003), indicating their importance to the functions of HARE. PNGaseF treatment releases ~25 kDa of glycans from either isoform
and from either rat or human native or recombinant HARE
(Zhou et al. 1999, 2002, 2003). The same result was obtained
with membrane-bound or soluble 190-HARE or 315-HARE.
Glycans identified at the 10 sites (Figure 1) ranged in mass
from 1580 Da to 3866 Da (7 to 16 sugars) corresponding to a
total average mass of ~25 kDa. Thus, most of the N-glycans
attached to the full-length protein may be within its C-terminal 190-HARE region.
Several groups discovered that N- or O-glycans can influence the HA-binding function of proteins containing a
Link module (Bennett et al. 1995; Katoh et al. 1995; Lesley
et al. 1995; Bartolazzi et al. 1996; Dasgupta et al. 1996; English et al. 1998; Skelton et al. 1998). Although initially controversial, it is now generally accepted that N-glycans on the
Link module of the HA receptor CD44 influence HA binding. In most cases, the presence of an N-glycan inhibits HA
binding. The HA-binding ability of LYVE-1, a lymphatic HA
receptor, is inhibited by sialylation of O-glycans (Nightingale et al. 2009), and HA binding could be unmasked in sialylated native or recombinant LYVE-1 by neuraminidase
treatment. Locations of the sialylated O-glycans are unknown, but thought not to be on the LYVE-1 Link module.
Inhibition due to the presence of a glycan can sometimes be
attributed to steric occlusion; HA cannot physically interact
with key binding site residues. Another attractive and inherently more responsive mechanism would involve reversible interactions between an oligosaccharide and domains
within the protein to create an unfavorable conformation for
HA binding (i.e. a temporary self-occluding steric effect). Reversing or disrupting this oligosaccharide interaction to allow a conformation favorable for HA binding might occur
by multiple mechanisms, such as an allosteric-like response
upon binding another protein or small ligand or by removing sialic acid residues needed to maintain the unfavorable
conformation.
In summary, our results show that lack of an N-glycan
on the HARE Link domain: (i) compromises HA binding
to purified ecto-domain in three of four in vitro assays and
(ii) does not decrease HA binding or endocytosis mediated
by the membrane-bound protein. These effects indicate that
N2280 oligosaccharides are important for the soluble truncated ecto-domain to maintain an HA binding conformation. Despite the ability of 190-HARE(N2280A) cells to internalize HA normally, preliminary results indicate that this
variant HARE mediates little or no HA-dependent intracellular ERK activation (M.S. Pandey and P.H. Weigel unpublished). As noted above, the HARE Link glycans may directly interact (or indirectly facilitate interaction) with an
adjacent HARE domain near the membrane to create an active HA binding site and ERK signaling competence. Supporting the idea that these activities depend on specific conformations, we previously found that the ability of mAb-174
to block HA binding by HARE in rat liver sinusoidal en-
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dothelial cells was lost at lower temperature (Weigel et al.
2003). We concluded that HARE undergoes a conformation
change between 37°C and 4°C that does not prevent HA
binding to HARE but that alters the epitope recognized by
mAb-174 so that it does not block HA binding. Based on the
present results, this conformational change is likely dependent on the Link domain glycan.
Materials and methods
Reagents and buffers
Flp-In 293 cells, culture medium, transfection reagents,
cDNA purification and amplification reagents and plasmids were from Invitrogen-Gibco (Carlsbad, CA). pfu ultra HF was from Stratagene (La Jolla, CA). EasyTag Expre35S35S Labeling Mix (35S-Methionine/Cysteine) was
from Perkin Elmer (Waltham, MA). Classic Blue BX film
was from MidSci (St. Louis, MO). Streptavidin (SA), biotin-LC-hydrazide, sulfo-NHS-SS-biotin, SnakeSkin dialysis
tubing (MWCO 3500) and luminol and peroxide solutions
were from Pierce (Rockford, IL). RNA purification kits were
from Qiagen, and plasmid DNA purification and cloning
kits were from Fermentas (Glen Burnie, MD). Polysorp well
strips were from Nunc (Roskilde, Denmark), and p-nitrophenylphosphate was from Kirkegaard & Perry Laboratories, Inc. (Gaithersburg, MD). HA from Genzyme (Framingham, MA) was acid-hydrolyzed under mild conditions (Raja
et al. 1988), neutralized, size fractionated and weight-average mass was determined by light scattering (Baggenstoss
and Weigel 2006). Biotinylated HA (b-HA; 108 kDa) was
prepared by the method of Yu and Toole (1995), with slight
modifications (Harris et al. 2007). Sodium 125I (100 mCi/mL;
specific activity of >0.6 TBq/mg) in NaOH and Sepharose
6 Fast Flow (Nickel NTA) resin were from GE/Amersham
Biosciences (Piscataway, NJ). 125I-SA and 125I-HA were prepared as described previously (Weigel 1980; Raja et al. 1984;
McGary et al. 2003). Concentrator/desalting Centricon devices were from Amicon (Bedford, MA). Endo-H (Streptomyces plicatus) was from Calbiochem (San Diego, CA). SAalkaline phosphatase conjugate, TFMS, trypsin and other
salts and reagents were from Sigma-Aldrich (St. Louis, MO).
PNGase-F (Flavobacterium meningosepticum), formic acid
and sequence grade chymotrypsin, Asp-N, chymotrypsin/
trypsin and Asp-N/Glu-C were from Roche Applied Science (San Francisco, CA). TFMS was from Acros Chemicals
(Geel, Belgium). TBST contains 20 mM Tris–HCl, pH 7.0,
150 mM NaCl and 0.1% (v/v) Tween-20. Hank’s balanced
salt solution (HBSS) contains 5 mM KCl, 0.4 mM KH2PO4,
pH 7.2, 0.8 mM MgSO4, 137 mM NaCl, 0.3 mM Na2HPO4,
5.5 mM glucose, 1.26 mM CaCl2, 0.5 mM MgCl2 and 28 μM
phenol red.
Purification of 190-HARE ecto-domains
Recombinant s190-HARE, s190-HARE(N2280A) or s190HARE(ΔLink) was purified from conditioned cell culture
medium by immobilized Ni-chelate affinity chromatography
as described previously (Harris et al. 2007). Protein content,
here and in general, was determined by A280 or by a dyebinding method (Bradford 1976). Eluted fractions (pooled
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and concentrated using a 30 MWCO concentrator) were 10–
20% pure, since some bovine serum proteins (e.g. α-2 macroglobulin and H factor 1/complement) copurified. Impurities
were removed after 5% SDS–PAGE (Laemmli 1970) by excising s190-HARE bands. After overnight electroelution (35 V,
4°C) and subsequent concentration (Harris et al. 2007), the
recovered s190-HARE was >98% pure, as assessed by SDS–
PAGE and silver staining.
Trypsin digestion of s190-HARE prior to N-glycan
determination
Partially purified s190-HARE was fractionated by SDS–
PAGE (Novex NuPAGE Tris-Acetate gel system; Invitrogen) and the gel stained by colloidal Coomassie. The
s190-HARE band, identified by parallel western blotting
(Burnette 1981), was excised and reduced in-gel in 600 mM
Tris–HCl, pH 8.4, containing 2 mg/mL dithiothreitol (37°C
for 45 min) and then carboxymethylated by addition of
12 mg/mL iodoacetic acid (22°C for 1 h). Carboxymethylation was terminated by dialysis against 50 mM NH4HCO3,
pH 8.5, at 4°C for 48 h, followed by lyophilization. Alkylated s190-HARE was incubated with trypsin (50:1 ratio,
w/w) in 50 mM (NH4)HCO3, pH 8.4, for 16 h at 37°C. The
digestion was terminated by heating at 100°C for 3 min,
followed by C18 Sep-Pak chromatography (Waters Corp.,
Milford, MA, USA). Bound peptides were eluted with either 20% (v/v) or 40% (v/v) propanol in 5% aqueous acetic
acid, pooled and lyophilized.
Preparation of N-glycans
PNGase-F (3 Roche units) digestion of tryptic peptides prepared above or from the whole s190 was carried out in
50 mM ammonium bicarbonate, pH 8.5, for 16 h at 37°C. Released N-glycans were separated from peptides using SepPak C18 cartridges (Waters Corp.) and permethylated using a
sodium hydroxide procedure (Dell et al. 1993).
Digestion of s190-HARE for glycoproteomic studies
Gel-purified 190-HARE was reduced and alkylated as described above and digested with trypsin, chymotrypsin,
Asp-N, Asp-N/Glu-C, chymotrypsin/trypsin or chymotrypsin/trypsin/Asp-N as described previously (Dell et al. 1993,
1994). For CNBr cleavage, an aliquot of tryptically digested
s190-HARE was dried down and resuspended in 100 μL
of a 1 mL solution of 8 CNBr crystals dissolved in 70% formic acid. Samples were incubated at 22°C overnight and reactions then stopped by adding 4 volumes of water and
lyophilization.
MS for glycan determination
MALDI-TOF MS data were acquired on a Voyager-DE
sSTR mass spectrometer (PerSeptive Biosystems, Framingham, MA) in the reflectron mode with delayed extraction. Permethylated samples were dissolved in 10 µL of
80% (v/v) methanol in water, and 1 µL of dissolved sample was premixed with 1 µL of matrix (10 mg/mL 2,5-dihydroxybenzoic acid in 80% (v/v) aqueous methanol) before
loading onto a metal plate. MALDI-TOF/TOF experiments
were performed on a 4800 Proteomics Analyzer (Applied
Biosystems, Framingham, MA) in reflectron positive-ion
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mode. Both 2,5-dihydroxybenzoic acid and α-cyano-4hydroxycinnamic acid matrices (10 mg/mL in 50% (v/v)
acetonitrile in 0.1% (v/v) aqueous trifluoroacetic acid)
were used in conjunction with setting the potential difference between the source acceleration voltage and the collision cell at 1 kV to obtain different degrees and patterns of
fragmentation.
MS for peptide mapping
Digests were analyzed by nano-LC-ESI-MS/MS using a reverse-phase nano-high-performance liquid chromatography (HPLC) system (Dionex, Sunnyvale, CA) connected to
a quadrupole TOF mass spectrometer (Q-STAR Pulsar I,
MDS Sciex). Components were separated by using a binary
nano-HPLC gradient generated by an Ultimate pump fitted with a Famos autosampler and a Switchos microcolumn
switching module (LC Packings, Amsterdam, The Netherlands). An analytical C18 nanocapillary (75 µm inside diameter × 15 cm, PepMap) and a micro precolumn C18 cartridge
were employed for on-line peptide separation. The digest
was first loaded onto the precolumn and eluted with 0.1%
formic acid (Sigma) in water for 4 min. The eluent was then
transferred onto an analytical C18 nanocapillary HPLC column and eluted at a flow rate of 150 nL/min using the following gradient of solvent A [0.05%, v/v formic acid in a
95:5, v/v water/acetonitrile mixture] and solvent B [0.04%
formic acid in a 95:5, v/v acetonitrile/water mixture]: 99% A
from 0 to 5 min, 99–90% A from 5 to 10 min, 90–60% A from
10 to 70 min, 60–50% A from 70 to 71 min, 50–5% A from
71 to 75 min, 5% A from 75 to 85 min, 5–95% A from 85 to
86 min and 95% A from 86 to 90 min. Data acquisition was
performed using Analyst QS software with an automatic information-dependent acquisition function.
Glycosidase treatments
Cells were lysed in phosphate buffered saline (PBS) with
0.5% NP-40 containing protease inhibitors, debris was removed by centrifugation and membrane-bound HARE was
collected by incubation for 2 h at 22°C with 20 μL of a 1:1
suspension of mAb-30 (Zhou et al. 2000) coupled to CNBractivated Sepharose 4B (1 mg/mL resin). After centrifugation, the supernatant was removed and PBS (20 μL) and 0.5%
SDS (5 μL) were added to the resin, which was incubated at
22°C for 10 min to dissociate HARE. The sample was centrifuged, the supernatant containing HARE was placed in a
0.2 mL screw cap microfuge tube and NP-40 was added to
a final concentration of 2%. PNGase-F or Endo-H (1.25 mU)
was added and the sample incubated for 16 h at 37°C. For
purified soluble HARE proteins, 0.5 μg of protein in 2%
NP-40 in PBS was incubated with enzyme under the same
conditions.
Chemical deglycosylation
Five micrograms of s190-HARE was lyophilized in a 1.5 mL
tube and placed on ice. TFMS (70 μL) was mixed with 7.5 μL
anisole, cooled on ice and added to the sample. The tube
was shaken gently (not vortexed) until the protein was dissolved and the mixture incubated for 3 h on ice with occasional mixing. Pyridine was chilled to −20°C in an ethanol/
dry ice bath, and 2 μL of 0.2% bromophenol blue in ethanol
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(as a pH indicator) was added to the protein mixture. The
red TFMS protein solution was cooled to −20°C and cold
pyridine added until the solution turned yellow. To prevent
solidification, 10 μL of water was added. More pyridine was
added slowly, to minimize exothermic heating, until the solution was purple/blue. Deglycosylated HARE was then dialyzed in three changes of 500 mL PBS over 10 h and stored
at −80°C.
Preparation of s190-HARE(N2280A) and
190-HARE(N2280A) constructs
To make a N2280A mutant, two primers (forward:
5′-CTATGGACCTAGACCCGCCAAGAGTGAAATGTGGG-3′ and reverse: 5′-CCCACATTTCACTCTTGGCGGGTCTAGGTCCATAG-3′) (altered codon is underlined)
were used in individual mutagenic reactions with the WT
190-HARE cDNA (in pSecTag/FRT/V5/His) in an Ericomp thermocycler (18 cycles: 94°C, 20 s; 62°C, 20 s; 71°C,
1 min/plasmid kb) using pfu Ultra HF. Plasmids were ethanol precipitated, resuspended in 17 μL H2O, 2 μL NEB4 buffer and 2.5 U of DpnI to cut template plasmids while retaining intact mutant plasmids. After overnight incubation at
37°C, the digestion mixtures were heated to 95°C for 10 min
and immediately transformed into E. cloni 10G super-competent E. coli cells (Lucigen, Middleton, WI). Bacterial cells
were screened by a mini-prep procedure, PCR and DNA
sequencing to confirm the mutation. Plasmids with correct mutations, open reading frames and promoter regions
were used to make stable cell lines. A cDNA construct encoding the secreted ecto-domain was then produced from
a validated 190-HARE(N2280A) cDNA using the primer
(5′-GTGACCTTGACCCACACTGGATCCGAAGGTAAGCCTATC-3′) to delete the transmembrane and cytoplasmic domains, while retaining C-terminal V5 and His6 epitopes (Harris et al. 2007).
Creation of Flp-In 293 cell lines expressing soluble or membrane-bound 190-HARE(N2280A)
Cell lines with a single identical chromosome insertion site
were created using recombinase-mediated integration in
human Flp-In 293 cells (embryonic kidney derived) as described previously (Harris et al. 2004, 2007). Multiple clones
were tested for HARE expression by SDS–PAGE (5% gels)
and western analysis (Burnette 1981) with anti-V5 Ab. Each
positive clone was then tested for correct insertion of the
pSecTag(190HARE) cDNA into the unique chromosomal
Flp-In recombination site, mediated by the Flp-In recombinase encoded by pOG44, using the assays described earlier
(Harris et al. 2004, 2007).
HA endocytosis assays
WT 190-HARE, EV, 190-HARE(ΔLink) and 190-HARE
(N2280A) cells were grown in 24-well plates to ~90% confluence, washed and incubated in serum-free medium at 37°C
for 1 h. Cells were washed with 1 mL HBSS and incubated
at 37°C for the indicated times in 0.4 mL of Dulbecco’s modified Eagle’s medium (DMEM) containing 0.05% bovine serum albumin and 1.0 µg/mL 125I-HA with or without a 100fold excess of unlabeled HA to assess nonspecific or total
uptake, respectively. Medium was aspirated and cells were
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washed three times with 1 mL HBSS, solubilized in 1 mL
0.3 N NaOH, and radioactivity (using a gamma counter) and
protein were determined. Multiple experiments were performed with different combinations of control and N2280A
cell lines. Since receptor expression often differs among cell
lines, HARE content was quantified by western analysis using 10 μg of cell lysate (in triplicate) and enhanced chemiluminescence according to the manufacturer’s instructions using Classic Blue BX film. Digital images were captured using
a FluoroChem 8000 imaging system (Alpha Innotech Corporation, San Leandro, CA), and band densities were quantified as integrated densitometry values (i.e. the sum of all
pixel values minus background correction). Values for specific endocytosis (total minus nonspecific) are presented as
CPM/μg cell lysate protein (normalized to the mean integrated digital value of each mutant compared to WT, which
was 100%).
35S

Pulse-chase metabolic labeling
190-HARE and 315-HARE cells were grown in DMEM with
8% FBS and 100 μg/mL hygromycin B in 6-well dishes for
2 days. Confluent cells were then washed twice with PBS, incubated in DMEM without Met/Cys for 45 min, washed and
1.0 mL of 37°C DMEM with 200 mCi/mL 35S-Met/Cys (no
unlabeled Met/Cys) was added to each well. After 10 min at
37°C, the media were aspirated, and the cells were washed
twice in PBS and then incubated in fresh DMEM with 8%
FBS at 37°C. At the indicated chase times, 0.5 mL of 4°C
DMEM with 1.5% NP-40 and protease inhibitors was added,
lysates were centrifuged to clear debris and HARE was removed by incubation overnight at 4°C with CNBr-activated
Sepharose 4B coupled to three anti-HARE mAbs (30, 154 and
159). The resin was washed, bound proteins released with
SDS, separated by 5% SDS–PAGE, and the gel was dried on
filter paper and subjected to autoradiography using BioMax
MS film (Kodak) for 2–7 days at −80°C.
In vitro assays for HA binding to HARE ecto-domains
ELISA-Like Assay. HA (142 kDa) and T-10 dextran (as a
control) were mixed separately in PBS at 50 μg/mL and incubated overnight in heparin-binding plates (BD Biosciences, San Jose, CA, USA). After blocking with 0.2% (w/v)
gelatin in 0.2% (v/v) Tween-20, 100 mM NaCl, 50 mM sodium acetate, pH 7.2, the wells were washed and incubated
with 1.0 μg/mL purified soluble WT, N2280A or ΔLink
190-HARE ecto-domains for 1.5 h at 37°C. The wells were
washed with 100 mM NaCl, 50 mM sodium acetate, 0.2%
(v/v) Tween-20, pH 7.2 three times, and bound HARE was
detected with anti-V5 Ab and alkaline phosphatase-anti goat
IgG and color development using p-nitrophenylphosphate
was quantified at A405 over 30 min.
Ligand Blot Assay. Cell pellets were resuspended in 0.5%
NP-40 with protease inhibitors, and 20 mg of total protein
was separated by 5% (w/v) SDS–PAGE. Gels were electrotransferred to nitrocellulose and incubated with 125I-HA as
described previously (Yannariello-Brown et al. 1996). After washing, bound 125I-HA was detected by autoradiography using Kodak BioMax MS film. The blots were then
processed for western analysis to identify HARE as noted
above.
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HA-HARE Pull-Down Assay. SA-Agarose CL-4B (25 μL,
50% slurry; Fluka, Sigma-Aldrich) was mixed by rotation
with 100 nM b-HA in TBST for 1 h at 22°C in a 1.5 mL tube.
The resin was washed three times by centrifugation in TBST
and incubated for 1 h at 37°C in 1 mL of TBST with 1 μg of
s190-HARE, s190-HARE(N2280A) or s190-HARE(ΔLink).
The resin was then washed three times with TBST, resuspended in 20 μL of 4× Laemmli buffer (Laemmli 1970) and
subjected to 5% SDS–PAGE and western blotting using antiV5 Ab. HARE was visualized as above, and the bands were
digitized and compared to the total protein used to assess
the fraction bound to HA.
SPR Assay. Experiments were performed at 37°C on a Biacore 3000 (Biacore AB [GE Healthcare] Uppsala, Sweden).
b-HA was captured on research grade SA-coated sensor
chips (Sensor Chip SA, Biacore Inc.) pretreated according to
the manufacturer’s instructions. A solution of b-HA (1.0 μg/
mL) was injected at 30 μL/min in PBS, pH 7, containing
0.005% Tween 20 until a saturating amount of HA was captured on the surface (600 RU). The control surface contained
only pretreated SA without b-HA on the same sensor chip.
The specific HA binding of purified s190-HARE WT (positive control), ΔLink (negative control) and N2280A variant
ecto-domains were measured using the Biacore 3000 in-line
reference subtraction feature. Two concentrations (12.5 and
50 nM) of each analyte were used to evaluate the kinetics of
association (kon) and dissociation (koff, assessed in the same
buffer without ecto-domain) at a flow rate of 5 μL/min over
both surfaces of the sensor chip. Regeneration of the chip by
stripping the analyte from the HA was performed by washing all surfaces with 5 M urea containing 0.2% SDS. Association and dissociation rate constants were calculated using 1:1
Langmuir modeling by the Biaevaluation software v3.2.
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